Standard chemotherapy combination (Cyclophosphamide, Hydroxydaunorubicin, Vincristine, Prednisolone [CHOP]) with 1, 3 or 6 cycles of the monoclonal anti-CD20-antibody. Rituximab in first line therapy of follicular non-Hodgkin?s lymphoma.

niversity of Heidelberg (Germany)0 个研究点目标入组 120 人开始时间: 2006年1月6日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Patients with histologically proven CD20+ follicular lymphoma (follicular lymphoma grade I, II), stage III and IV
•2. Age >18 years, no upper limit
•3. No pre-treatment except irradiation and/or corticosteroids
•4. Requirement of therapy: one or more of the following: B-symptoms, hematopoietic insufficiency (leukopenia <1.5/nl, anemia hb <10 g/dl, platelets <100/nl)
•5. Objective tumor progression (>50% increase in sum of tumor diameters in six months); 'bulky disease' (mediastinal/abdominal tumor >7.5 cm and/or other lymphnodes >5 cm)

•1. Age <18 years
•2. Stage I or II
•3. CD20 negativity
•4. Karnofsky Index <80% or Eastern Cooperative Oncology Group (ECOG) >2
•5. Pre-treatment with murine antibodies, severe organ impairment (heart, lung, neck) according to common criteria
•6. Pre-treatment with any chemotherapy

发起方

niversity of Heidelberg (Germany)